Shire (SHP) PT Lowered to GBX 4,000 at Credit Suisse Group


The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Credit Suisse Group's price target would suggest a potential upside of 24.92% from the company's previous close.



from Biotech News